For more information, contact

Division of Tuberculosis Elimination

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Coordinating Center for Infectious Diseases
Centers for Disease Control and Prevention
1600 Clifton Road NE
MS E-10
Atlanta, GA 30333

Phone: (404) 639-8120 Fax: (404) 639-8959

E-mail: TBInfo@cdc.gov Web address: http://www.cdc.gov/tb/

Tuberculosis Information Management System (TIMS)

TIMS Help Desk: (404) 639-8444

Ordering Information

Copies of *Reported Tuberculosis in the United States*, 2007, are available from the Division of Tuberculosis Elimination's online ordering system at http://www.cdc.gov/tb/.

This report is also accessible via the internet at http://www.cdc.gov/tb/

Suggested Citation: CDC. *Reported Tuberculosis in the United States, 2007.* Atlanta, GA: U.S. Department of Health and Human Services, CDC, September 2008.

All material in this report is in the public domain and may be reproduced or copied without permission. However, citation as to source is requested.

Reported Tuberculosis in the United States

2007

Publication Year 2008

Reported Tuberculosis in the United States, 2007

Centers for Disease Control and Prevention Coordinating Center for Infectious Diseases National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination

September 2008

Centers for Disease Control and PreventionJulie L. Gerberding, M.D., M.P.H Directo
Coordinating Center for Infectious Diseases
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB PreventionKevin Fenton, M.D., Ph.D Directo
Division of Tuberculosis Elimination
Surveillance, Epidemiology, and Outbreak Investigations BranchThomas R. Navin, M.D. Chie
Surveillance TeamValerie Robison, D.D.S., M.P.H., Ph.D
Field Services and Evaluation BranchKashef Ijaz, M.D
Data Management and Statistics BranchJosé E. Becerra, M.D., M.P.H

This report was prepared by

Surveillance Team Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention

Valerie Robison, D.D.S., M.P.H., Ph.D.
Carla Jeffries, M.P.H.¹
Robert Pratt, B.S.¹
Ryan MacLaren Wallace, M.P.H.
Elvin Magee, M.P.H., M.S.
Lori Armstrong, Ph.D.
Carla Winston, Ph.D.
Lilia P. Manangan, R.N., M.P.H.
Glenda T. Newell
Emily G. Capilouto

Others contributing to the production of this publication

Office of the Director

Philip LoBue, M.D., FACP, FCCP

Data Management and Statistics Branch The Tuberculosis Information and Management System Support Team

Sandy Price, P.M.P.¹ Bruce Bradley, M.P.A. Stacey Parker¹ Vic Bowker¹

Surveillance, Epidemiology, and Outbreak Investigations Branch Mitesh Desai, M.D., M.P.H.

National Center for Health Marketing, Division of Creative Services Brenda Holmes

Field Services and Evaluation Branch

We also acknowledge and thank

All state and local health departments throughout the United States whose staff collected and reported the data used in this publication.

Cover image reprinted with permission ©2008 American Lung Association

For more information about the American Lung Association or to support the work it does, call 1-800
LUNG-USA (1-800-586-4872) or log on to www.lungusa.org.

¹CDC Information Technology Support Contractor

Preface

Reports of verified cases of tuberculosis (RVCT) are submitted to the Division of Tuberculosis Elimination (DTBE), Centers for Disease Control and Prevention (CDC), by 60 reporting areas (the 50 states, the District of Columbia, New York City, Puerto Rico, and seven other jurisdictions in the Pacific and Caribbean). In January 1993, an expanded system was developed to collect additional information for each reported TB case in order to better monitor trends in TB and TB control. A software package (SURVS-TB) for data entry, analysis, and transmission of case reports to CDC was designed and implemented as part of the expanded TB surveillance system. In 1998, the Tuberculosis Information Management System (TIMS) replaced SURVS-TB.

This publication, Reported Tuberculosis in the *United States, 2007*, presents the summary data for TB cases reported to CDC, verified, and counted for 2007. It is similar to previous publications (see page xi, #19) and contains six major sections. The first section presents trends in the overall TB case counts and case rates by selected demographic and clinical characteristics. The second section presents overall case counts and case rates for the United States by selected demographic characteristics for 2007. In the third section, TB case counts and case rates are presented by state and other jurisdictions with tables of selected demographic and clinical characteristics. In the fourth section, data collected as part of the expanded system (e.g., initial drug resistance, HIV status) are presented by reporting area. Select tables report data from the Pacific and Caribbean jurisdictions. The fifth section provides TB case counts and case rates by metropolitan statistical areas (MSAs: see Technical Notes, page 9, for further details) with tables of selected demographic and clinical characteristics. Finally, the sixth section presents figures from the annual surveillance slide set, which emphasize key recent trends in TB epidemiology in the United States. The slides with accompanying text can

also be viewed and downloaded from the DTBE home page, which is accessible via the Internet at http://www.cdc.gov/tb/.

To help interpret the data, an Executive Commentary (page 3) and Technical Notes (page 9) have been included. In addition, the current case definition (MMWR 1997;46 [No. RR 10]:40-41) and "Recommendations for Counting Reported Tuberculosis Cases" are provided in Appendices A and B, respectively (page 119). The recommendations for counting TB cases, which update the original January 1977 recommendations, were first published in *Reported Tuberculosis in the United States*. 1996.

After the publication of updated Guidelines for Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection in April 2000¹, DTBE, CDC, began receiving reports of serious adverse events (i.e., hospitalization or death) related to the use of a 2-month course of rifampin and pyrazinamide (RZ) for treatment of latent tuberculosis infection (TLTBI). Subsequently, DTBE requested and received reports and conducted on-site investigations of liver injury in persons on TLTBI, and treatment guidelines were revised accordingly.²

Severe adverse events among persons receiving TLTBI continue to be a public health concern, and data on the annual number and trends of such events are needed. To this end, DTBE organized a working group on TLTBI adverse events in September 2003. This working group was charged with the development of a national surveillance system with the following objectives:

To assist public health officials, policy makers, and healthcare providers in the prevention of adverse events, and To serve as the basis for periodic evaluation of guidelines for TLTBI and revision of these guidelines as needed.

Development of the National System for Severe Adverse Events Associated with Treatment of LTBI has been implemented, and will include formal collaborations among CDC, FDA, and other participating agencies to ensure interagency notification of serious adverse events. Mechanisms for quality assurance and timely dissemination of data are also under development.

At present, DTBE urges hospices, hospitals, jails, prisons, and private medical offices to report, through their local health departments, all severe adverse events (e.g., liver injury, metabolic acidosis, anaphylaxis, seizure, severe dermatitis) leading to hospitalization or death of a person receiving TLTBI that occurred after January 1, 2004, to DTBE by telephone (404-639-8401) or e-mail (LManangan@cdc.gov).

References

- 1. ATS/CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221–S247.
- 2. American Thoracic Society/CDC. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR* 2003;52(31):735–9.

Previous Statistical Reports in this Series:

- 1. Special Tuberculosis Projects, 1961–1965. Atlanta: CDC; 1966.
- 2. Special Tuberculosis Projects, December 1965. Atlanta: CDC; 1966.
- 3. Special Tuberculosis Projects, June 1966. Atlanta: CDC; 1967.
- 4. Special Tuberculosis Projects, December 1966. Atlanta: CDC; 1967.
- 5. Summary Report. Atlanta: CDC; 1967.
- 6. Special Tuberculosis Projects, June 1967. Atlanta: CDC; 1968.
- 7. Tuberculosis Program Reports, December 1967. Atlanta: CDC; 1968.
- 8. Tuberculin testing during 1966–1967 school year. In: *Tuberculosis Program Reports*. Atlanta: CDC; 1968.
- 9. Tuberculosis Program Reports: Six Month Period Ending June 1968. Atlanta: CDC; 1969.
- 10. Program Performance Analyses, June–December 1968. In: *Tuberculosis Program Reports*. Atlanta: CDC; 1970.
- 11. Tuberculin testing data, 1967–1968 school year. In: *Tuberculosis Program Reports*. Atlanta: CDC; 1970.
- 12. The project years, 1961–1969, In: *Tuberculosis Program Reports*. Atlanta: CDC; 1970.
- 13. Tuberculosis programs (for years 1970–1973). In: *Tuberculosis Program Reports*. Atlanta: CDC: 1971–1974.
- 14. Reported Tuberculosis Data (for years 1962–1973). Atlanta: CDC; 1963–1974.
- 15. Tuberculosis Statistics: States and Cities (for years 1974–1985). Atlanta: CDC; 1971–1986.
- 16. Tuberculosis in the United States (for years 1974–1986). Atlanta: CDC; 1976–1987.
- 17. Tuberculosis program management in the United States, 1984. In: *Tuberculosis Program Reports*. Atlanta: CDC; 1986.
- 18. Tuberculosis Statistics in the United States (for years 1987–1992). Atlanta: CDC: 1989–1993.
- 19. Reported Tuberculosis in the United States (for years 1993–2006). Atlanta: CDC: 1994–2007.

Reports from 1999 through 2007 are available on the Internet at http://www.cdc.gov/tb/surv/default.htm.

State TB Statistics on the Internet*

ΑL http://www.adph.org/tb/ AK http://www.epi.alaska.gov/id/tb.stm AR None AZhttp://www.azdhs.gov/phs/oids/tuberculosis http://ww2.cdph.ca.gov/programs/tb/Pages/default.aspx CA CO http://www.cdphe.state.co.us/dc/tb/tbhome.html CT http://www.dph.state.ct.us/bch/infectiousdise/tbstatis.htm DC None DE http://www.dhss.delaware.gov/dph/dpc/tuberculosis.html FLhttp://www.doh.state.fl.us/disease ctrl/tb/ GA http://health.state.ga.us/epi/tuber.asp http://www.hawaii.gov/health/tb HI IΑ http://www.idph.state.ia.us/adper/tb control.asp ID None http://www.idph.state.il.us/health/infect/reportdis/tb.htm Π IN http://www.in.gov/isdh/19662.htm KS http://www.kdheks.gov/tb/statistical information.html KY http://chfs.ky.gov/dph/tb.htm http://www.dhh.louisiana.gov/offices/?ID=273 LA MA http://www.mass.gov/dph/cdc/tb/index.htm MD http://www.edcp.org/tb/index.html ME http://www.maine.gov/dhhs/boh/ddc/tuberculosis control.htm http://www.michigan.gov/tb MI MN http://www.health.state.mn.us/divs/idepc/diseases/tb/stats.html MO http://www.ddhss.mo.gov/Tuberculosis.index.html http://www.dphhs.mt.gov/PHSD/epidemiology/commun-disease-epi-tuberculosis.shtml MT http://www.msdh.state.ms.us/msdhsite/static/14,0,125.html MS ND http://www.health.state.nd.us/disease/tb/ NC http://www.epi.state.nc.us/epi/tb NE http://www.dhhs.ne.gov/cod/Tuberculosis/tbindex.htm NH http://www.dhhs.nh.gov/DHHS/CDCS/LIBRARY/ Fact+Sheet/tb-reference.htm NJ http://www.state.nj.us/health/cd/tbhome.htm NM http://www.health.state.nm.us/PHD/Infectious Diseases/TB/2007 NM TB CaseRates.pdf NYC http://www.nyc.gov/html/doh/html/tb/tb-reports.shtml NV http://health.nv.gov/index.php?option=com content&task= view&id=208&Itemid=348 NY None OH http://www.odh.ohio.gov/healthstats/disease/tb/tb1.aspx OK http://www.health.ok.gov/program/tb/index.html OR http://oregon.gov/DHS/ph/tb/ PA http://www.health.state.pa.us/PHP/TB/tb.htm http://www.health.ri.gov/disease/communicable/tb/index.php RI PR http://www.salud.gov.pr/Programas/ProgramaTuberculosis/ Pages/DatosEstadisticosTuberculosis.aspx SC http://www.scdhec.net/health/disease/tb/index.htm SD http://doh.sd.gov/tb TN http://health.state.tn.us/ceds/TB/index.htm TX http://www.dshs.state.tx.us/idcu/disease/tb/statistics/ UT http://www.health.utah.gov/cdc/tb home.htm VA http://www.vdh.virginia.gov/epidemiology/DiseasePrevention/Programs/Tuberculosis/Epidemiology/ VT None WA http://www.doh.wa.gov/cfh/tb

http://www.dhfs.wisconsin.gov/tb

http://www.wvtb.org

WI

WV

WY http://www.health.wyo.gov/PHSD/tb/index.html

^{*}As reported to CDC by U.S. reporting area TB programs as of July 2008. Includes responses from the reporting areas of New York City (NYC) and Puerto Rico (PR).

Contents

Acknowledgmentsvii
Prefaceix
Previous Statistical Reports in this Seriesxi
State TB Statistics on the Internetxii
Executive Commentary
Technical Notes 9
Morbidity Trend Tables, United States
Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates per
100,000 Population, and Percent Change: United States, 1953–2007
Table 2. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Hispanic
Ethnicity and non-Hispanic Race: United States, 1993–2007
Table 3. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Race Only:
United States, 1993–2007
Table 4. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Age
Group: United States, 1993–2007
Table 5. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Origin of
Birth: United States, 1993–2007
Table 6. Tuberculosis Cases and Percentages Among Foreign-born Persons by the Top 30
Countries of Origin of Birth: United States, 2003–2007
Table 7. Tuberculosis Cases and Percentages Among Adult Foreign-born Persons by Country of Origin and Years in the United States Before TB Diagnosis, Top 30 Countries: United States,
2007 and 199720
Table 8. Tuberculosis Cases and Percentages by Case Verification Criterion and Site of Disease:
United States, 1993–200721
Table 9. Pulmonary Tuberculosis Cases and Percentages by Sputum Smear and Sputum Culture
Results: United States, 1993–200721
Table 10. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug Resistance in
Persons with No Previous History of TB, by Origin of Birth: United States, 1993–200722
Table 11. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug Resistance in
Persons with Previous History of TB, by Origin of Birth: United States, 1993–200722

Table 12. Percentages of Tuberculosis Cases by Initial Drug Regimen, Use of Directly Observed
Therapy (DOT), and Completion of Therapy (COT): United States, 1993–200723
Table 13. Tuberculosis Cases and Percentages in Persons with HIV Test Results and with HIV
Coinfection, by Age Group: United States, 1993–2006
Table 14. Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Stopped: United
States, 1993–2005
Morbidity Tables, United States, 2007
Table 15. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age
Group: United States, 2007
Table 16. Tuberculosis Case Rates per 100,000 Population by Hispanic Ethnicity and Non-
Hispanic Race, Sex, and Age Group: United States, 2007
Table 17. Tuberculosis Cases in U.Sborn Persons by Hispanic Ethnicity and Non-Hispanic
Race, Sex, and Age Group: United States, 2007
Table 18. Tuberculosis Cases in Foreign-born Persons by Hispanic Ethnicity and Non-Hispanic
Race, Sex, and Age Group: United States, 2007
Table 19. Tuberculosis Cases by Country of Origin: United States, 2007
Morbidity Tables, States, 2007
Table 20. Tuberculosis Cases and Case Rates per 100,000 Population: States, 2007 and 200637
Table 21. Tuberculosis Cases and Percentages by Age Group: Reporting Areas, 200738
Table 22. Tuberculosis Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race:
Reporting Areas, 2007
Table 23. Tuberculosis Cases and Percentages, U.Sborn and Foreign-born Persons: States,
200742
Table 24. Tuberculosis Cases and Percentages in Foreign-born Persons by Country of Origin:
States, 2007
Table 25. Tuberculosis Cases and Percentages in Foreign-born Persons by Number of Years in
the United States: States, 2007
Table 26. Tuberculosis Cases and Percentages by Pulmonary and Extrapulmonary Disease:
Reporting Areas, 2007
Table 27. Extrapulmonary Tuberculosis Cases and Percentages by Site of Disease: Reporting
Areas, 2007

Table 28. Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and Grouped by	y
Number of Cases: States and the District of Columbia, 2007 and 2006	.50
Morbidity Tables, Reporting Areas, 2007 and 2005	
Table 29. Tuberculosis Cases and Percentages by Residence in Correctional Facilities, Age >1	5:
Reporting Areas, 2007	.53
Table 30. Tuberculosis Cases and Percentages by Homeless Status, Age >15: Reporting Areas	3,
2007	.54
Table 31. Tuberculosis Cases and Percentages by Residence in Long-term Care Facilities, Ag	e
>15: Reporting Areas, 2007	.55
Table 32. Tuberculosis Cases and Percentages by Injecting Drug Use, Age >15: Reporting	
Areas, 2007	.56
Table 33. Tuberculosis Cases and Percentages by Noninjecting Drug Use, Age >15: Reporting	g
Areas, 2007	57
Table 34. Tuberculosis Cases and Percentages by Excess Alcohol Use, Age >15: Reporting	
Areas, 2007	.58
Table 35. Tuberculosis Cases and Percentages by Initial Drug Regimen: Reporting Areas,	
2007	.59
Table 36. Culture-Positive Tuberculosis Cases and Percentages with Drug Susceptibility Resu	lts,
by Resistance to INH or Multidrug Resistance: Reporting Areas, 2007	.60
Table 37. Tuberculosis Cases and Percentages Among Persons Aged 25-44 by HIV Status:	
Reporting Areas, 2007	.61
Table 38. Tuberculosis Cases and Percentages by Occupation, Age >15: Reporting Areas,	
2007	.62
Table 39. Tuberculosis Cases and Percentages by Type of Health Care Provider: Reporting	
Areas, 2005	.63
Table 40. Tuberculosis Cases and Percentages by Directly Observed Therapy (DOT): Reporting	ıg
Areas, 2005	.64
Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT)	:
Reporting Areas, 2005	.65
Table 42. Tuberculosis Cases and Percentages by Reason Therapy Stopped: Reporting Areas,	
2005	.66
Table 43. Completion of Tuberculosis Therapy (COT) Cases and Percentages by Hispanic	
Ethnicity and Non-Hispanic Race: Reporting Areas, 2005	.67

Table 44. Tuberculosis Cases and Percentages in Persons Completing Therapy for Whom	
Therapy Was Indicated for One Year or Less: Reporting Areas, 2001–2005	68
Morbidity Tables, Cities and Metropolitan Statistical Areas, 2007	
Table 45. Tuberculosis Cases in Selected Cities: 2007 and 2006	71
Table 46. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan Statistic	cal
Areas with ≥500,000 Population, 2007 and 2006	72
Table 47. Tuberculosis Cases by Pulmonary and Extrapulmonary Disease: Metropolitan	
Statistical Areas with ≥500,000 Population, 2007	74
Table 48. Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with ≥500,000	
Population, 2007	76
Table 49. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan	Statis-
tical Areas with ≥500,000 Population, 2007	78
Table 50. Tuberculosis Cases and Percentages, U.Sborn Persons and Foreign-born Persons	s:
Metropolitan Statistical Areas with ≥500,000 Population, 2007	80
Surveillance Slide Set, 2007	
Slides	85
Text	111
Appendices	
Appendix A: Tuberculosis Case Definition for Public Health Surveillance	119
Appendix B: Recommendations for Counting Reported Tuberculosis Cases	120
Index	130